Xtant Medical (XTNT) swings to Q2 2026 loss and cuts full-year revenue guidance
Rhea-AI Filing Summary
Xtant Medical Holdings, Inc. reported weaker results for the quarter ended June 30, 2026. Revenue was $23.0 million, down from $35.4 million a year earlier, mainly due to the sale of Coflex/CoFix and international hardware assets and the non-recurrence of high-margin license revenue tied to Q-code and amniotic membrane agreements.
Gross margin fell to 57.9% from 68.6%, reflecting the loss of high-margin license revenue, reduced production efficiencies, and higher excess and obsolete inventory charges. Operating expenses rose to $22.5 million from $19.7 million, driven by a $5.0 million exclusivity fee related to a new U.S. distribution agreement with Dilon Technologies. The company swung to a net loss of $9.4 million from net income of $3.6 million, and non-GAAP adjusted EBITDA declined to a loss of $2.7 million from positive $6.9 million.
As of June 30, 2026, Xtant held $9.9 million in cash and cash equivalents and $23.0 million of total indebtedness. Management modestly reduced full-year 2026 revenue guidance to $99–$103 million, from $101–$105 million, citing lower-than-expected biologics revenue and ongoing headwinds in its amnio product line. Strategically, Xtant launched Trivium™ Shaped and secured exclusive U.S. rights to Dilon’s HEMOBLAST® Bellows, adding a ~20-person sales team.
Positive
- The company reduced total indebtedness to $23.0 million as of June 30, 2026, from $25.4 million at December 31, 2025, including a $3.8 million term loan principal reduction funded in part by divestiture proceeds.
- Xtant executed strategic initiatives, including an exclusive U.S. distribution agreement for HEMOBLAST® Bellows with Dilon Technologies and the launch of Trivium™ Shaped, expanding its biologics portfolio and adding an approximately 20-person sales team.
- Management states it believes that current cash of $9.9 million and $0.7 million of revolver availability are sufficient to fund operations, as currently planned, for at least the next 12 months.
Negative
- Second quarter 2026 revenue declined to $23.0 million from $35.4 million in 2025, a sharp drop driven by asset divestitures and loss of prior-year license revenue.
- Profitability deteriorated significantly, with a net loss of $9.4 million versus net income of $3.6 million a year earlier, and non-GAAP adjusted EBITDA moving from $6.9 million positive to a $2.7 million loss.
- Gross margin compressed to 57.9% from 68.6%, reflecting the end of high-margin license revenue, lower production efficiency, and higher excess and obsolete inventory charges.
- Operating cash flow for the first half of 2026 was a use of $9.4 million, compared with positive $2.6 million in the prior-year period, indicating more cash-intensive operations.
- The company booked a $5.0 million write-off of a distribution agreement deposit in the quarter, materially increasing operating expenses.
- Full-year 2026 revenue guidance was reduced to $99–$103 million from $101–$105 million, reflecting softer biologics revenue and headwinds in the amnio product line.
Filing Explained
At June 30, the company reported cash and separate revolving-credit availability, while management said planned operations had at least 12 months of funding.
The
The filing presents the
For historical context, the Q1 cash balance of
Sources and calculations
- Xtant Medical Holdings, Inc. Form 8-K and Exhibit 99.1 (2026-08-11)
- Form 8-K purpose (2026-07-17)
- Xtant Medical Holdings, Inc. 2026 first-quarter fundamentals (2026Q1)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $12,137,000 / ($2,114,000 / 90) = [object Object]
8-K Event Classification
Key Figures
Key Terms
non-GAAP adjusted EBITDA financial
Q-code regulatory
HEMOBLAST® Bellows medical
distribution agreement deposit financial
advanced wound care market medical
Earnings Snapshot
For full-year 2026, the company guides revenue to a range of $99 million to $103 million, lowered from prior guidance of $101 million to $105 million due to softer biologics revenue and headwinds in its amnio product line.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Xtant Medical (XTNT) perform financially in the second quarter of 2026?
What happened to Xtant Medical (XTNT) margins and adjusted EBITDA in Q2 2026?
What is Xtant Medical’s (XTNT) updated 2026 revenue guidance?
What is Xtant Medical’s (XTNT) liquidity and debt position as of June 30, 2026?
What strategic initiatives did Xtant Medical (XTNT) undertake in Q2 2026?
Why did Xtant Medical’s (XTNT) revenue decline so sharply year over year in Q2 2026?
How is Xtant Medical (XTNT) using non-GAAP adjusted EBITDA in its reporting?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| ||
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On August 11, 2026, Xtant Medical Holdings, Inc. (the “Company”) announced its financial results for the second quarter of 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
To supplement its consolidated financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”), the Company uses certain non-GAAP financial measures, such as non-GAAP adjusted EBITDA, which are included in the press release furnished as Exhibit 99.1 to this report. The Company defines non-GAAP adjusted EBITDA as net income (loss) from operations before depreciation and amortization expense; interest expense, net; and tax benefit (expense), and as further adjusted to add back in or exclude, non-cash compensation and unrealized foreign currency translation losses or gains and other special items, including write-off of distribution agreement deposit, divestiture/acquisition-related income and expenses and income related to transition services agreements, acquisition-related fair value adjustments, and separation-related expenses, in each case as applicable.
The Company uses non-GAAP adjusted EBITDA in making operating decisions because it believes this measure provides meaningful supplemental information regarding its core operational performance. Additionally, this measure gives the Company a better understanding of how it should invest in sales and marketing and research and development activities and how it should allocate resources to both ongoing and prospective business initiatives. The Company also uses non-GAAP adjusted EBITDA to help make budgeting and spending decisions, for example, among sales and marketing expenses, general and administrative expenses, and research and development expenses. Additionally, the Company believes its use of non-GAAP adjusted EBITDA facilitates management’s internal comparisons to historical operating results by factoring out potential differences caused by charges not related to its regular, ongoing business, including, without limitation, non-cash charges and certain large and unpredictable charges or gains.
As described above, the Company excludes the effect of the following items from its non-GAAP adjusted EBITDA for the following reasons:
Non-cash compensation. The Company excludes non-cash compensation, which is a non-cash charge related to equity awards granted by the Company. Although non-cash compensation is a recurring charge to the Company’s operations, management has excluded it because it relies on valuations based on future events, such as the market price of the Company’s common stock, that are difficult to predict and are affected by market factors that are largely not within the control of the Company. Thus, management believes that excluding non-cash compensation facilitates comparisons of the Company’s operational performance in different periods, as well as with similarly determined non-GAAP financial measures of comparable companies.
Unrealized foreign currency translation gains or losses. The Company excludes unrealized foreign currency translation gains or losses, as applicable, from non-GAAP adjusted EBITDA primarily because such gains or losses are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Write-off of distribution agreement deposit. The Company excludes the write-off of a distribution deposit from non-GAAP adjusted EBITDA primarily because such write-off is not reflective of the Company’s ongoing operating results and is not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Divestiture/acquisition-related expenses and income related to transition services agreements. The Company excludes expenses and income directly related to the Company’s divestitures and acquisitions and subsequent integration and transition activities from non-GAAP adjusted EBITDA primarily because such expenses and income are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. These expenses and income include legal and accounting fees, as well fees charged by the Company in connection with post-divestiture transition services performed for divested operations. These expenses and income are not considered normal, recurring, cash operating expenses/income necessary to operate the Company’s business. The Company further believes that excluding these expenses and income from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Acquisition-related fair value adjustments. The Company excludes acquisition-related fair value adjustments from non-GAAP adjusted EBITDA primarily because such adjustments are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Separation-related expenses. The Company excludes separation-related expenses primarily because such expenses are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period over-period comparability.
Non-GAAP adjusted EBITDA is reconciled to net income (loss), the most directly comparable GAAP measure in the press release. The Company also presents in the press release EBITDA as a percentage of total revenue and adjusted EBITDA as a percentage of total revenue and reconciles these two non-GAAP measures in the press release to net income (loss) as a percentage of total revenue.
Non-GAAP financial measures are not in accordance with, or an alternative for, GAAP measures and may be different from non-GAAP financial measures used by other companies. In addition, non-GAAP financial measures are not based on any comprehensive or standard set of accounting rules or principles. Accordingly, the calculation of the Company’s non-GAAP financial measures may differ from the definitions of other companies using the same or similar names, limiting, to some extent, the usefulness of such measures for comparison purposes. Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with the Company’s financial results as determined in accordance with GAAP. Non-GAAP financial measures should only be used to evaluate the Company’s financial results in conjunction with the corresponding GAAP measures. Accordingly, the Company qualifies its use of non-GAAP financial information in a statement when non-GAAP financial information is presented.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit No. |
Description | |
| 99.1 |
|
Press Release of Xtant Medical Holdings, Inc. dated August 11, 2026 entitled “Xtant Medical Reports Second Quarter 2026 Financial Results” (furnished herewith) |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| XTANT MEDICAL HOLDINGS, INC. | ||
| By: | /s/ Scott C. Neils | |
| Scott C. Neils | ||
| Chief Financial Officer | ||
Date: August 11, 2026
Exhibit 99.1
Xtant Medical Reports Second Quarter 2026 Financial Results
Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures
Company to host investor conference call and webcast today, August 11th, at 8:30am ET
BELGRADE, Mont., August 11, 2026 — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the second quarter ended June 30, 2026.
Second Quarter 2026 Financial Highlights
| ● | Generated total revenue of $23.0 million for the second quarter of 2026, as compared to $35.4 million for the second quarter of 2025. The decline in revenue relates primarily to the sale of the non-core Coflex/CoFix assets and international hardware business to Companion Spine in December 2025 as well as license revenue that ceased at the end of 2025 due to changes in the reimbursement environment. |
Second Quarter 2026 and Recent Business Highlights
| ● | Announced an exclusive U.S. distribution agreement with privately held Dilon Technologies whereby Xtant has acquired the exclusive U.S. commercial rights to Dilon’s HEMOBLAST® Bellows product for high-performance hemostasis following certain surgical procedures. As part of the transaction, Xtant has hired Dilon’s approximately 20-person U.S. sales team, who will support Xtant’s entire biologics portfolio. | |
| ● | Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures. Trivium™ Shaped is available in pre-shaped configurations designed to support handling, preparation, and placement across a range of surgical applications. |
Sean Browne, President and CEO of Xtant Medical, stated, “The second quarter reflected continued execution of our strategy to broaden our core biologics portfolio while expanding access to more hospitals and surgeons. The Dilon distribution agreement added a complementary hemostatic technology and significant commercial resources, which, together with the introduction of Trivium Shaped, strengthen our platform and position us for sustained long-term growth.”
Second Quarter 2026 Financial Results
Revenue for the second quarter of 2026 was $23.0 million, compared to $35.4 million for the same period in 2025. The year-over-year decline is primarily due to the sale of the Company’s non-core Coflex/CoFix assets and international hardware business to Companion Spine in December of 2025, as well as license revenue from Xtant’s Q-code and amniotic membrane agreements in the second quarter of 2025 that did not repeat in the second quarter of 2026 due to changes in the reimbursement environment.
Gross margin for the second quarter of 2026 was 57.9%, compared to 68.6% for the same period in 2025. The decrease was primarily due to the cessation of Q-code high-margin license revenue from the amniotic membrane agreements that ceased at the end of 2025, together with reduced production efficiencies and increased charges for excess and obsolete inventory.
Operating expenses for the second quarter of 2026 totaled $22.5 million, compared to $19.7 million for the second quarter of 2025. The increase was primarily due to a $5.0 million exclusivity fee paid to Dilon Technologies in connection with the Company’s distribution agreement, partially offset by lower general and administrative and sales and marketing expenses following the Company’s December 2025 sale of its Coflex/CoFix assets and international hardware business to Companion Spine.
Second quarter 2026 net loss was $9.4 million, compared to net income of $3.6 million for the second quarter of 2025.
Non-GAAP adjusted EBITDA loss for the second quarter of 2026 totaled $2.7 million, compared to positive adjusted EBITDA of $6.9 million for the same period in 2025.
The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest income/expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, the write-off of the distribution agreement deposit, disposition/acquisition-related income and expenses, acquisition-related fair value adjustments, unrealized foreign currency translation gain or loss, and separation-related expenses. A calculation and reconciliation of adjusted EBITDA to net income (loss) can be found in the attached financial tables.
As of June 30, 2026, the Company had $9.9 million of cash and cash equivalents, total indebtedness of $23.0 million, and availability under its revolving credit facility of $0.7 million, compared to $17.3 million of cash and cash equivalents, total indebtedness of $25.4 million, and availability under its revolving credit facility of $3.8 million as of December 31, 2025. The decrease in total indebtedness reflects a $3.8 million reduction in term loan principal, including $2.8 million from proceeds received from Companion Spine in the first quarter of 2026, partially offset by net borrowings of $1.1 million under the Company’s revolving credit facility during the first half of 2026, used primarily to fund the $5.0 million exclusivity fee paid to Dilon Technologies and for working capital.
The Company believes its current cash and availability under its credit facility are sufficient to fund operations, as currently planned, for at least the next 12 months.
2026 Financial Guidance
Reflecting lower-than-expected biologics revenue in the second quarter, as well as ongoing headwinds related to its amnio product line directly tied to the advanced wound care market, Xtant is today modestly reducing its full-year guidance to a range of $99 million to $103 million, from $101 million to $105 million previously.
Conference Call
Xtant Medical will host a webcast and conference call to discuss its second quarter 2026 financial and operating results at 8:30 am ET today, August 11, 2026.
To access the webcast: https://www.webcaster5.com/Webcast/Page/3039/54128
To access the conference call, dial 888-506-0062 (US) or 973-528-0011 (International) and reference Participant Access Code 844793.
A replay of the call will be available on the Investor section of the Company’s website at www.xtantmedical.com for a period of one year.
About Xtant Medical Holdings, Inc.
Xtant Medical’s mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Non-GAAP Financial Measures
To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including adjusted EBITDA, adjusted EBITDA as a percentage of total revenue. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in this release or tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” ‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’ “continue,” “future,” ‘‘will,’’ “potential,” “guidance,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s full year 2026 revenue guidance. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results, financial performance and need for additional capital; the Company’s ability to achieve sustained long-term growth; the success of the distribution arrangement and the HEMOBLAST® Bellows product, including future U.S. sales and the additional U.S. sales personnel and their impact on the Company’s business and operating results; the possibility that the distribution agreement may be terminated by either party and the effect of any such termination on the Company and its ability to recapture the $5.0 million exclusivity fee it paid Dilon; the effect of the distribution agreement on the Company’s business, including its relationships with other distributors, independent sales representatives and personnel, and its business and operating results; the ability of Dilon to continue to manufacture and supply the Company the HEMOBLAST® Bellows product and the effect of any such non-performance on the Company and its business and operating results; the success of the Company’s expanded field sales force to improve the Company’s reach and leverage its contract portfolio and independent agent network; the Company’s ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with acquisitions and dispositions; its ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess and obsolete inventory; its ability to continue to innovate, develop and introduce new products and the success of those products; its ability to remain competitive; its ability to engage and retain new and existing independent distributors and agents and qualified sales and other personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of inflation, elevated interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on its financial results; the effect of government and third-party coverage and reimbursement for its products; its ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; its ability to license intellectual property on commercially reasonable terms and to maintain any such licenses and its ability to obtain and protect its intellectual property and proprietary rights and operate without infringing the rights of others; its ability to service its debt, comply with debt covenants, and access additional indebtedness or financing on favorable terms or at all, if and when needed; and other factors described in its Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 30, 2026 and subsequent SEC reports, including its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 to be filed with the SEC on or about August 11, 2026. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
Investor Relations Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
– Tables Follow –
XTANT MEDICAL HOLDINGS, INC.
Consolidated Balance Sheets
(In thousands, except number of shares and par value)
| As of June 30, 2026 | As of December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 9,870 | $ | 17,053 | ||||
| Restricted cash | 347 | 275 | ||||||
| Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $2,234 and $2,165, respectively | 19,416 | 17,803 | ||||||
| Inventories | 33,287 | 30,263 | ||||||
| Note receivable | — | 10,462 | ||||||
| Prepaid and other current assets | 1,857 | 2,389 | ||||||
| Total current assets | 64,777 | 78,245 | ||||||
| Property and equipment, net | 5,542 | 6,202 | ||||||
| Right-of-use asset, net | 2,894 | 3,192 | ||||||
| Goodwill | 6,074 | 6,074 | ||||||
| Intangible assets, net | 252 | 299 | ||||||
| Other assets | 128 | 133 | ||||||
| Total Assets | $ | 79,667 | $ | 94,145 | ||||
| LIABILITIES & STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 6,154 | $ | 3,844 | ||||
| Accrued liabilities | 7,481 | 10,626 | ||||||
| Current portion of long-term debt | 3,720 | 3,500 | ||||||
| Current portion of lease liability | 594 | 622 | ||||||
| Current portion of finance lease obligations | 29 | 35 | ||||||
| Line of credit | 11,985 | 10,857 | ||||||
| Total current liabilities | 29,963 | 29,484 | ||||||
| Long-term Liabilities: | ||||||||
| Lease liability, less current portion | 2,397 | 2,665 | ||||||
| Finance lease obligation, less current portion | — | 12 | ||||||
| Long-term debt, plus premium and less issuance costs | 7,287 | 11,026 | ||||||
| Other liabilities | 5 | 5 | ||||||
| Total Liabilities | 39,652 | 43,192 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders’ Equity: | ||||||||
| Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — | ||||||
| Common stock, $0.000001 par value; 300,000,000 shares authorized; 140,262,960 shares issued and outstanding as of June 30, 2026 and 140,039,557 shares issued and outstanding as of December 31, 2025 | — | — | ||||||
| Additional paid-in capital | 307,004 | 305,439 | ||||||
| Accumulated other comprehensive loss | (1 | ) | — | |||||
| Accumulated deficit | (266,988 | ) | (254,486 | ) | ||||
| Total Stockholders’ Equity | 40,015 | 50,953 | ||||||
| Total Liabilities & Stockholders’ Equity | $ | 79,667 | $ | 94,145 | ||||
XTANT MEDICAL HOLDINGS, INC.
Consolidated Statements of Operations
(Unaudited, in thousands, except number of shares and per share amounts)
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | ||||||||||||||||
| Product revenue | $ | 23,031 | $ | 30,436 | $ | 43,915 | $ | 59,720 | ||||||||
| License revenue | — | 4,975 | — | 8,595 | ||||||||||||
| Total Revenue | 23,031 | 35,411 | 43,915 | 68,315 | ||||||||||||
| Cost of sales | 9,701 | 11,127 | 18,614 | 23,788 | ||||||||||||
| Gross Profit | 13,330 | 24,284 | 25,301 | 44,527 | ||||||||||||
| Operating Expenses | ||||||||||||||||
| General and administrative | 6,436 | 7,478 | 12,709 | 15,011 | ||||||||||||
| Sales and marketing | 10,368 | 11,616 | 18,554 | 22,820 | ||||||||||||
| Research and development | 695 | 566 | 1,130 | 1,009 | ||||||||||||
| Write-off of distribution agreement deposit | 5,000 | — | 5,000 | — | ||||||||||||
| Total Operating Expenses | 22,499 | 19,660 | 37,393 | 38,840 | ||||||||||||
| (Loss) Income from Operations | (9,169 | ) | 4,624 | (12,092 | ) | 5,687 | ||||||||||
| Other Expense | ||||||||||||||||
| Interest expense | (542 | ) | (1,004 | ) | (1,141 | ) | (2,049 | ) | ||||||||
| Interest income | 1 | — | 220 | — | ||||||||||||
| Unrealized foreign currency translation gain | 23 | 178 | 22 | 202 | ||||||||||||
| Other income (expense) | 347 | 7 | 589 | (2 | ) | |||||||||||
| Total Other Expense | (171 | ) | (819 | ) | (310 | ) | (1,849 | ) | ||||||||
| Net (Loss) Income from Operations Before Provision for Income Taxes | (9,340 | ) | 3,805 | (12,402 | ) | 3,838 | ||||||||||
| Provision for Income Taxes Current and Deferred | (73 | ) | (255 | ) | (100 | ) | (230 | ) | ||||||||
| Net (Loss) Income | $ | (9,413 | ) | $ | 3,550 | $ | (12,502 | ) | $ | 3,608 | ||||||
| Net (Loss) Income Per Share: | ||||||||||||||||
| Basic | $ | (0.07 | ) | $ | 0.03 | $ | (0.09 | ) | $ | 0.03 | ||||||
| Dilutive | $ | (0.07 | ) | $ | 0.02 | $ | (0.09 | ) | $ | 0.02 | ||||||
| Shares used in the computation: | ||||||||||||||||
| Basic | 140,258,667 | 139,310,589 | 140,159,255 | 139,190,378 | ||||||||||||
| Dilutive | 140,258,667 | 148,574,242 | 140,159,255 | 148,339,423 | ||||||||||||
XTANT MEDICAL HOLDINGS, INC.
Consolidated Statements of Cash Flows
(Unaudited, in thousands)
| Six Months Ended June 30, | ||||||||
| 2026 | 2025 | |||||||
| Operating activities: | ||||||||
| Net (loss) income | $ | (12,502 | ) | $ | 3,608 | |||
| Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities: | ||||||||
| Depreciation and amortization | 1,042 | 2,243 | ||||||
| Loss (gain) on sale of fixed assets | 5 | (49 | ) | |||||
| Non-cash interest | 251 | 289 | ||||||
| Stock-based compensation | 1,621 | 1,524 | ||||||
| Provision for reserve on accounts receivable | 463 | 395 | ||||||
| Provision for excess and obsolete inventory | 1,496 | 490 | ||||||
| Write-off of distribution agreement deposit | 5,000 | — | ||||||
| Other | 3 | 46 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (2,076 | ) | (6,873 | ) | ||||
| Inventories | (3,591 | ) | (1,349 | ) | ||||
| Prepaid and other assets | (298 | ) | 347 | |||||
| Accounts payable | 2,309 | (880 | ) | |||||
| Accrued liabilities | (3,145 | ) | 2,763 | |||||
| Net cash (used in) provided by operating activities | (9,422 | ) | 2,554 | |||||
| Investing activities: | ||||||||
| Purchases of property and equipment | (441 | ) | (1,557 | ) | ||||
| Proceeds from sale of fixed assets | 102 | 97 | ||||||
| Distribution agreement deposit | (5,000 | ) | — | |||||
| Proceeds from divestitures | 10,368 | — | ||||||
| Net cash provided by (used in) investing activities | 5,029 | (1,460 | ) | |||||
| Financing activities: | ||||||||
| Borrowings on line of credit | 27,895 | 51,812 | ||||||
| Repayments on line of credit | (26,767 | ) | (51,925 | ) | ||||
| Payments on long-term debt | (3,771 | ) | — | |||||
| Debt issuance costs | — | (49 | ) | |||||
| Payments on financing leases | (18 | ) | (34 | ) | ||||
| Payment of taxes from withholding of common stock on settlement of restricted stock units | (56 | ) | (61 | ) | ||||
| Net cash used in financing activities | (2,717 | ) | (257 | ) | ||||
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | (1 | ) | (21 | ) | ||||
| Net change in cash and cash equivalents and restricted cash | (7,111 | ) | 816 | |||||
| Cash and cash equivalents and restricted cash at beginning of period | 17,328 | 6,221 | ||||||
| Cash and cash equivalents and restricted cash at end of period | $ | 10,217 | $ | 7,037 | ||||
| Reconciliation of cash and cash equivalents and restricted cash reported in the condensed consolidated balance sheets | ||||||||
| Cash and cash equivalents | $ | 9,870 | $ | 6,923 | ||||
| Restricted cash | 347 | 114 | ||||||
| Total cash and restricted cash reported in condensed consolidated balance sheets | $ | 10,217 | $ | 7,037 | ||||
XTANT MEDICAL HOLDINGS, INC.
CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA
(in thousands)
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net (Loss) Income | $ | (9,413 | ) | $ | 3,550 | $ | (12,502 | ) | $ | 3,608 | ||||||
| Depreciation and amortization | 508 | 1,169 | 1,042 | 2,243 | ||||||||||||
| Interest expense, net | 541 | 1,004 | 921 | 2,049 | ||||||||||||
| Tax expense | 73 | 255 | 100 | 230 | ||||||||||||
| Non-GAAP EBITDA | (8,291 | ) | 5,978 | (10,439 | ) | 8,130 | ||||||||||
| Net (Loss) Income/Total Revenue | (40.9 | )% | 10.0 | % | (28.5 | )% | 5.3 | % | ||||||||
| Non-GAAP EBITDA/Total Revenue | (36.0 | )% | 16.9 | % | (23.8 | )% | 11.9 | % | ||||||||
| NON-GAAP ADJUSTED EBITDA CALCULATION | ||||||||||||||||
| Non-cash compensation | 875 | 766 | 1,621 | 1,524 | ||||||||||||
| Write-off of distribution agreement deposit | 5,000 | — | 5,000 | — | ||||||||||||
| Divestiture/acquisition-related expenses | (283 | ) | 295 | (518 | ) | 295 | ||||||||||
| Acquisition-related fair value adjustments | 44 | 60 | 95 | 171 | ||||||||||||
| Unrealized foreign currency translation gain | (23 | ) | (178 | ) | (22 | ) | (202 | ) | ||||||||
| Separation related expenses | — | (17 | ) | — | 23 | |||||||||||
| Non-GAAP Adjusted EBITDA | $ | (2,678 | ) | $ | 6,904 | $ | (4,263 | ) | $ | 9,941 | ||||||
| Non-GAAP Adjusted EBITDA/Total Revenue | (11.6 | )% | 19.5 | % | (9.7 | )% | 14.6 | % | ||||||||